Showing 759 news articles about Hepatitis C treatment

Filters Content type: Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

New & experimental hepatitis C treatment

Polymerase Inhibitor PSI-7977 Works with Interferon or Companion Drug

Editor's pick
HIVandhepatitis.com
5 April 2011
New & experimental hepatitis C treatment

First Sustained Response Data for Polymerase Inhibitor Mericitabine

Editor's pick
HIVandhepatitis.com
5 April 2011
New & experimental hepatitis C treatment

Avalanche of hepatitis C products on the way

Editor's pick
Pharma Times
4 April 2011
New & experimental hepatitis C treatment

Bristol-Myers Interferon-Free Combo Cured Hepatitis Patients

Editor's pick
Bloomberg
4 April 2011
New & experimental hepatitis C treatment

Merck, J&J’s New Hepatitis C Treatments Fetch $31,000 in France

Editor's pick
Bloomberg
4 April 2011
New & experimental hepatitis C treatment

Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients at EASL 2011

Editor's pick
Business Wire
4 April 2011
New & experimental hepatitis C treatment

Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment

Editor's pick
Eurekalert HIV
2 April 2011
Hepatitis C transmission & prevention

First vaccine for viral hepatitis C could become a reality

Editor's pick
Eurekalert Inf Dis
1 April 2011
New & experimental hepatitis C treatment

Inhibitex Reports Positive Safety and Antiviral Data from Its Phase 1b Study of HCV Nucleotide Inhibitor INX-189

Editor's pick
Pipeline Review
1 April 2011
New & experimental hepatitis C treatment

'Fantastic' data on Novartis' first-in-class hep C antiviral

Editor's pick
Pharma Times
1 April 2011
New & experimental hepatitis C treatment

Well-known statin could be recycled as HCV therapy supplement

Editor's pick
EASL
1 April 2011
Hepatitis C treatment

EASL Clinical Practice Guidelines: Management of Hepatitis C Virus Infection

Editor's pick
EASL
31 March 2011
New & experimental hepatitis C treatment

Interim Phase 2 Data Showed Rapid Viral Response to VX-222 in Combination with Telaprevir, Pegylated-Interferon and Ribavirin Among People With Hepatitis C

Editor's pick
Business Wire
31 March 2011
New & experimental hepatitis C treatment

Telaprevir Improves Viral Cure Rates After Previous Treatment Failure

Editor's pick
Poz magazine news
31 March 2011
New & experimental hepatitis C treatment

Pharmasset Initiates Phase 2b ATOMIC Trial of PSI-7977 for Multiple HCV Genotypes

Editor's pick
PR Newswire
30 March 2011
Hepatitis C treatment

Presidio Pharmaceuticals, Inc. Announces Positive Results in a Phase 1b Clinical Trial of PPI-461, a Novel, Potent Broadly-Active Hepatitis C Virus (HCV) Inhibitor

Editor's pick
Business Wire
30 March 2011
New & experimental hepatitis C treatment

Achillion ACH-1625 hepatitis drug shows promise in mid-stage trial

Editor's pick
Reuters
30 March 2011
Hepatitis C treatment

Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

Editor's pick
AIDSMeds
24 March 2011
Hepatitis C treatment

Copy of Reyataz May Be Safe for HIV-Positive People With Severe Liver Disease

Editor's pick
Kaiser Daily Global Health Policy Report
24 March 2011
New & experimental hepatitis C treatment

Next Stage for Biotron's Hep C Drug

Editor's pick
Hepatitis Central
23 March 2011
Hepatitis C treatment

More Support for Genetic Testing of Hepatitis C Patients

Editor's pick
Internal Medicine News
16 March 2011
New & experimental hepatitis C treatment

Telaprevir, Boceprevir for Hep C Approaching FDA Finish Line

Editor's pick
Poz
16 March 2011
New & experimental hepatitis C treatment

Copy of Telaprevir, Boceprevir for Hep C Approaching FDA Finish Line

Editor's pick
Poz
16 March 2011
Hepatitis C treatment

iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061

Editor's pick
PR Newswire
15 March 2011